New drug combination for lymphoma that has not responded
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new combination of drugs for people with aggressive B-cell lymphoma that has not gotten better or has come back. The goal is to see if the combination helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of aggressive B-cell lymphoma, like diffuse large B-cell lymphoma or mantle cell lymphoma.
- You are 18 years old or older.
- You have not had chemotherapy before.
- You are expected to live at least 3 more months.
- You do not have an active infection that needs treatment.
- You do not have unstable heart, liver, kidney, or metabolic disease.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—pola, zanubrutinib, and lenalidomide plus prednisone—for people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this treatment can control the disease and improve outcomes.
This trial tests a new combination of three drugs for people recently diagnosed with a type of lymphoma called large B-cell lymphoma. The goal is to see if this combination is safe and effective, and it might offer a new treatment option.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This study tests a combination of three newer targeted drugs for older adults (70+) who have just been diagnosed with diffuse large B-cell lymphoma and have not yet received any treatment. The goal is to see if this drug combo can control the lymphoma effectively while being manageable for older patients.
Hear when a new Aggressive B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.